Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): Good for Sulfonylureas?

  1. Lookup NU author(s)
  2. Dr Ebaa Al-Ozairi
  3. Professor Philip Home
Author(s)Al-Ozairi E, Sibal S, Home P
Publication type Article
JournalDiabetes Care
ISSN (print)0149-5992
ISSN (electronic)1935-5548
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
A Diabetes Outcome Progression Trial (ADOPT) was conceived in the hope that the seemingly inexorable decline in islet B-cell function described with metformin, sulfonylureas, and insulin in the UK Prospective Diabetes Study (UKPDS) might be stopped or inhibited to a major degree by peroxisome proliferator–activated receptor-γ agonists, in particular rosiglitazone (1,2). It was already well recognized that the rapid early efficacy of sulfonylureas in lowering glucose was not retained to 12 months, and that metformin and thiazolidinediones had slow onset of action over months, so the design of the study necessarily had to enable decline of measures of blood glucose control to be assessed for a considerable period from 1 year onwards. However, the extent (degree and time) to which this early efficacy of the sulfonylureas in protecting against hyperglycemia would persist was not accurately known. The study also provided a good opportunity to compare durability of effect of the three classes of drugs directly in the context of some shorter-term studies since published (3).
PublisherAmerican Diabetes Association
Actions    Link to this publication

Altmetrics provided by Altmetric